BSI utilizes a unique and proprietary monoclonal antibody-based proteomics technology to research and develop protein biomarkers. Their focus is on creating blood-based diagnostics for cancer and chronic diseases, with a particular emphasis on lung cancer diagnostics and screening. BSI's goal is to improve the productivity of drug discovery and development by enabling the creation of safer and more effective drugs at lower costs and in less time.